These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 23108144)
21. Successful cross-presentation of allogeneic myeloma cells by autologous alpha-type 1-polarized dendritic cells as an effective tumor antigen in myeloma patients with matched monoclonal immunoglobulins. Yang DH; Kim MH; Lee YK; Hong CY; Lee HJ; Nguyen-Pham TN; Bae SY; Ahn JS; Kim YK; Chung IJ; Kim HJ; Kalinski P; Lee JJ Ann Hematol; 2011 Dec; 90(12):1419-26. PubMed ID: 21465188 [TBL] [Abstract][Full Text] [Related]
22. Fully Synthetic Invariant NKT Cell-Dependent Self-Adjuvanting Antitumor Vaccines Eliciting Potent Immune Response in Mice. Chen PG; Hu HG; Sun ZY; Li QQ; Zhang BD; Wu JJ; Li WH; Zhao YF; Chen YX; Li YM Mol Pharm; 2020 Feb; 17(2):417-425. PubMed ID: 31841011 [TBL] [Abstract][Full Text] [Related]
23. Identification of canine natural CD3-positive T cells expressing an invariant T-cell receptor alpha chain. Yasuda N; Masuda K; Tsukui T; Teng A; Ishii Y Vet Immunol Immunopathol; 2009 Dec; 132(2-4):224-31. PubMed ID: 19748683 [TBL] [Abstract][Full Text] [Related]
25. Regulation of secondary antigen-specific CD8(+) T-cell responses by natural killer T cells. Hong C; Lee H; Park YK; Shin J; Jung S; Kim H; Hong S; Park SH Cancer Res; 2009 May; 69(10):4301-8. PubMed ID: 19401453 [TBL] [Abstract][Full Text] [Related]
26. [Development of a novel cancer cell therapy using enhanced cross-presentation of dendritic cells activated by innate lymphocyte]. Fujii S Rinsho Ketsueki; 2012 May; 53(5):504-14. PubMed ID: 22728552 [No Abstract] [Full Text] [Related]
27. Activated iNKT cells promote Vγ9Vδ2-T cell anti-tumor effector functions through the production of TNF-α. Schneiders FL; de Bruin RC; Santegoets SJ; Bonneville M; Scotet E; Scheper RJ; Verheul HM; de Gruijl TD; van der Vliet HJ Clin Immunol; 2012 Feb; 142(2):194-200. PubMed ID: 22122798 [TBL] [Abstract][Full Text] [Related]
28. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response. Strome SE; Voss S; Wilcox R; Wakefield TL; Tamada K; Flies D; Chapoval A; Lu J; Kasperbauer JL; Padley D; Vile R; Gastineau D; Wettstein P; Chen L Cancer Res; 2002 Mar; 62(6):1884-9. PubMed ID: 11912169 [TBL] [Abstract][Full Text] [Related]
29. Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients. Bonehill A; Van Nuffel AM; Corthals J; Tuyaerts S; Heirman C; François V; Colau D; van der Bruggen P; Neyns B; Thielemans K Clin Cancer Res; 2009 May; 15(10):3366-75. PubMed ID: 19417017 [TBL] [Abstract][Full Text] [Related]
30. DC therapy induces long-term NK reactivity to tumors via host DC. Shimizu K; Fujii S Eur J Immunol; 2009 Feb; 39(2):457-68. PubMed ID: 19180466 [TBL] [Abstract][Full Text] [Related]
31. Administration of alpha-galactosylceramide impairs the survival of dendritic cell subpopulations in vivo. Simkins HM; Hyde E; Farrand KJ; Ong ML; Degli-Esposti MA; Hermans IF; Ronchese F J Leukoc Biol; 2011 May; 89(5):753-62. PubMed ID: 21297009 [TBL] [Abstract][Full Text] [Related]
32. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Boczkowski D; Nair SK; Nam JH; Lyerly HK; Gilboa E Cancer Res; 2000 Feb; 60(4):1028-34. PubMed ID: 10706120 [TBL] [Abstract][Full Text] [Related]
33. Glycolipids injected into the skin are presented to NKT cells in the draining lymph node independently of migratory skin dendritic cells. Tripp CH; Sparber F; Hermans IF; Romani N; Stoitzner P J Immunol; 2009 Jun; 182(12):7644-54. PubMed ID: 19494288 [TBL] [Abstract][Full Text] [Related]
34. Potent anti-tumor responses to immunization with dendritic cells loaded with tumor tissue and an NKT cell ligand. Petersen TR; Sika-Paotonu D; Knight DA; Dickgreber N; Farrand KJ; Ronchese F; Hermans IF Immunol Cell Biol; 2010 Jul; 88(5):596-604. PubMed ID: 20142835 [TBL] [Abstract][Full Text] [Related]
36. Exploiting the CD1d-iNKT cell axis for potentiation of DC-based cancer vaccines. Lameris R; Schneiders FL; de Gruijl TD; van der Vliet HJ Methods Mol Biol; 2014; 1139():155-65. PubMed ID: 24619678 [TBL] [Abstract][Full Text] [Related]
37. Broadening the Message: A Nanovaccine Co-loaded with Messenger RNA and α-GalCer Induces Antitumor Immunity through Conventional and Natural Killer T Cells. Verbeke R; Lentacker I; Breckpot K; Janssens J; Van Calenbergh S; De Smedt SC; Dewitte H ACS Nano; 2019 Feb; 13(2):1655-1669. PubMed ID: 30742405 [TBL] [Abstract][Full Text] [Related]
38. Co-operation of α-galactosylceramide-loaded tumour cells and TLR9 agonists induce potent anti-tumour responses in a murine colon cancer model. Dong T; Yi T; Yang M; Lin S; Li W; Xu X; Hu J; Jia L; Hong X; Niu W Biochem J; 2016 Jan; 473(1):7-19. PubMed ID: 26450924 [TBL] [Abstract][Full Text] [Related]
39. Systemic DC Activation Modulates the Tumor Microenvironment and Shapes the Long-Lived Tumor-Specific Memory Mediated by CD8+ T Cells. Shimizu K; Yamasaki S; Shinga J; Sato Y; Watanabe T; Ohara O; Kuzushima K; Yagita H; Komuro Y; Asakura M; Fujii S Cancer Res; 2016 Jul; 76(13):3756-66. PubMed ID: 27371739 [TBL] [Abstract][Full Text] [Related]
40. Targeted Co-delivery of Tumor Antigen and α-Galactosylceramide to CD141 Huang J; Zhou J; Ghinnagow R; Seki T; Iketani S; Soulard D; Paczkowski P; Tsuji Y; MacKay S; Cruz LJ; Trottein F; Tsuji M Front Immunol; 2020; 11():2043. PubMed ID: 32973811 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]